摘要
Abstract
Objective To study the efficacy of Ivabradine in the treatment of chronic heart failure.Methods 80 patients with chronic heart failure who visited the Cardiovascular Department of Hanjiang Hospital in Putian,Fujian Province from July 2020 to July 2021 were collected.40 of them were served as the control group and received standardized anti heart failure treatment,including metoprolol tartrate sustained-release tablets,spironolactone,furosemide,and ramipril.The other 40 patients were selected to the observation group.On the base of the treatment of the control group,the observation group received Ivabradine if the heart rate still persisted at ≥70 beats/min when received evidence-based dosages of[3-blocker therapy.We compared the levels of N-terminal pro B type natriuretic peptide(NT proBNP),heart rate,cardiac function indicators,adverse reactions,quality of life scores,and efficacy evaluation between two groups.Results The observation showed that the creatine kinase(CK)and the left ventricular end diastolic diameter(LVEDD)in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The left ventricular ejection fraction(LVEF)and cardiac output(CO)in the observation group were higher than those in the control group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in NT proBNP levels and heart rate between the observation group and the control group before treatment(P＞0.05).After treatment,the NT proBNP levels and heart rate in the observation group were lower than those in the control group,and the difference was statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).The difference in quality of life between the observation group and the control group was statistically significant(P＜0.05).The effective rate of treatment in the observation group was 97.50％(39/40),and there was a statistically significant difference compared to that of the control group(80.00％(32/40))(P＜0.05).Conclusion During the treatment of chronic heart failure,the addition of Ivabradine can improve clinical symptoms while reducing the incidence of adverse reactions,improve cardiac function,lower NT proBNP levels,and stabilize various physical signs.关键词
伊伐布雷定/心力衰竭/NT-proBNPKey words
ivabredine/heart failure/NT proBNP分类
医药卫生
